A carregar...
The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidenc...
Na minha lista:
| Publicado no: | Cells |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7824419/ https://ncbi.nlm.nih.gov/pubmed/33375410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10010030 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|